Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Antibody therapy may enhance rituximab-mediated killing in non-Hodgkin's lymphoma

Dec. 17, 2004

Toll-like receptor agonist may be an effective immunotherapeutic approach to CLL

Dec. 17, 2004

Update on the efficacy and safety of MDX-060 in CD30-positive lymphoma

Dec. 16, 2004

Good tolerability profile found for DT388-IL-3 in AML

Dec. 16, 2004

FTC requests extension for review of MDX-010 collaboration

Dec. 14, 2004

First phase I/II data on the efficacy and safety of HuMax-CD20 in follicular lymphoma

Dec. 14, 2004

Swiss clearance for phase I study of 1D09C3

Dec. 13, 2004

Serono and Micromet sign collaboration and license agreement for MT-201

Dec. 13, 2004

Clinical responses seen in phase I/II study of Humax-CD20 in NHL

Dec. 10, 2004

Update on the survival effects of BLP-25 in NSCLC

Dec. 9, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...